Reviva Pharmaceuticals Holdings, Inc. (RVPH) company profile
Close on Oct 19, 2026Market cap $5.94MP/E –Yield –
About Reviva Pharmaceuticals
Pharmaceutical Preparations, SIC 2834
Reviva Pharmaceuticals Holdings, Inc. is a pharmaceutical company that focuses on the clinical development of therapeutic drug candidates. Its primary product candidate in development is brilaroxazine, a chemical compound under evaluation for the treatment of patients with schizophrenia. The company conducts clinical trials to assess the safety and efficacy of this candidate. Because Reviva is currently engaged in drug research and clinical trials, the text identifies no commercial operating segments, and its prospective users are individuals diagnosed with schizophrenia.
The company is incorporated in Delaware and maintains its principal executive offices in Cupertino, California. Reviva conducts its administrative and corporate affairs from this single facility in the United States. The provided text lists no additional offices, retail locations, or international operations. Its operational scope is centered on managing its clinical programs and research activities from its California headquarters.
Summary of the business section of Reviva Pharmaceuticals's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Reviva Pharmaceuticals Holdings, Inc.
- Headquarters
- Cupertino, CA
- Address
- 10080 N Wolfe Road, Suite Sw3-200 95014
- Phone
- (408) 501-8881
- Website
- revivapharma.com
- Employees
- 14, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Baker Tilly US, LLP, San Francisco, CA
Stock & identifiers
- Ticker
- RVPH
- Former tickers
- TZACU until Mar 22, 2021
- Exchange
- OTC
- IPO date
- Aug 22, 2018
- Shares outstanding
- 13M, Aug 13, 2026
- Public float
- $21.40M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-19.5 reverse, Mar 30, 2026; 1-for-20 reverse, Mar 9, 2026
- SEC CIK
- 1742927
- CUSIP
- 76152G209
- ISIN
- US76152G2093
- FIGI
- BBG00LJZ8FW8
- Share class FIGI
- BBG00LJZ8FX7
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Laxminarayan Bhat | President and CEO, Director | 2,484,244 |
| Narayan Prabhu | Chief Financial Officer | 100,000 |
| Parag Saxena | Director | 4,046,000 |
| Leslie D. Funtleyder | Director | – |
| Purav Patel | Director | 75,607 |
| Richard A. Margolin | Director | – |
Executive compensation, fiscal 2024
Summary compensation table from the latest proxy statement
| Executive | Salary | Bonus | Total | vs. prior year |
|---|---|---|---|---|
| Laxminarayan Bhat Chief Executive Officer and President(3) | $450.00K | $157.50K | $607.50K | -78% |
| Narayan Prabhu Chief Financial Officer(4) | $325.00K | $79.95K | $404.95K | -68% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
IPO
From the final prospectus (Form 424B4) and the first day of trading
SPAC offering
- Type
- SPAC (blank check) IPO of units
- Final prospectus filed
- Aug 22, 2018
- Securities offered
- 5,500,000
- Exchange
- Nasdaq
- First trading day
- Dec 15, 2020
- First-day close
- $8.08
- Lock-up ends (est.)
- Jun 13, 2021
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Employees
Headcount reported in annual reports
“We have fourteen full-time employees, and utilize consultants, a contract research organization (“CRO”) and third parties to perform our pre-clinical studies, clinical studies, manufacturing, regulatory, administrative, and financial functions.”
Corporate history
Events identified from SEC filings
See a number that looks wrong?